Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE
Rev Esp Cardiol (Engl Ed). 2017 Mar;70(3):186-193.
doi: 10.1016/j.rec.2016.08.004.
Epub 2016 Sep 9.
[Article in
English,
Spanish]
Authors
Oliver Husser
1
, Julio Núñez
2
, Christof Burgdorf
3
, Andreas Holzamer
4
, Christian Templin
5
, Thorsten Kessler
3
, Vicente Bodi
2
, Juan Sanchis
2
, Costanza Pellegrini
3
, Andreas Luchner
6
, Lars S Maier
6
, Christof Schmid
4
, Thomas F Lüscher
5
, Heribert Schunkert
7
, Adnan Kastrati
7
, Michael Hilker
4
, Christian Hengstenberg
8
Affiliations
- 1 Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany; Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany. Electronic address: oliver.husser@gmail.com.
- 2 Departamento de Cardiología, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia, Valencia, Spain.
- 3 Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany.
- 4 Klinik für Herz-, Thorax-, und herznahe Gefäßchirurgie, Universitätsklinikum Regensburg, Regensburg, Germany.
- 5 Universitäres Herzzentrum, Kardiologie, Universitätsspital Zürich, Zurich, Switzerland.
- 6 Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany.
- 7 Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung e.V., Partner Site Munich Heart Alliance, Munich, Germany.
- 8 Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany; Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung e.V., Partner Site Munich Heart Alliance, Munich, Germany.
Abstract
Introduction and objectives:
Conventional risk scores have not been accurate in predicting peri- and postprocedural risk of patients undergoing transcatheter aortic valve implantation (TAVI). Elevated levels of the tumor marker carbohydrate antigen 125 (CA125) have been linked to adverse outcomes after TAVI. We studied the additional value of CA125 to that of the EuroSCORE in predicting long-term mortality after TAVI.
Methods and results:
During a median follow-up of 59 weeks, 115 of 422 patients (27%) died after TAVI. Mortality was higher with elevated CA125 (> 30 U/mL) and EuroSCORE (> median) (47% vs 20%, P<.001 and 38% vs 16%, P<.001, respectively). In the multivariable analysis, CA125 (> 30 U/mL) remained an independent predictor of mortality (hazard ratio [HR], 2.16; 95% confidence interval [95%CI], 1.48-3.15; P<.001) and improved the predictive capability of the model (C-statistic: 0.736 vs 0.731) and the net reclassification index (51% 95%CI, 33-73) with an integrated discriminative improvement of 3.5% (95%CI, 0.5-8.4). A new variable (CA125-EuroSCORE) was created, with the combinations of the 2 possible binary states of these variables (+, elevated, -, not elevated; C1: CA125- EuroSCORE-; C2: CA125+ EuroSCORE-; C3: CA125- EuroSCORE+; C4: CA125+ EuroSCORE+). Patients in C1 exhibited the lowest cumulative mortality rate (14% [26 of 181]). Mortality was intermediate for C2 (CA125 > 30 U/mL and EuroSCORE ≤ median) and C3 (CA125 ≤ 30 U/mL and EuroSCORE > median): 27% (8 of 30) and 28% (37 of 131), respectively. Patients in C4 (CA125 > 30 U/mL and EuroSCORE > median) exhibited the highest mortality (55% [44 of 80], P-value for trend<.001).
Conclusions:
CA125 offers additional prognostic information beyond that obtained by the EuroSCORE. Elevation of both markers was associated with a poor prognosis.
Keywords:
EuroSCORE logístico; Implante percutáneo de válvula aórtica; Logistic EuroSCORE; Marcador tumoral antígeno carbohidrato 125; Predicción de riesgo; Risk prediction; Transcatheter aortic valve implantation; Tumor marker carbohydrate antigen 125.
Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Aged
-
Aortic Valve Stenosis / mortality
-
Aortic Valve Stenosis / surgery*
-
CA-125 Antigen / metabolism*
-
Female
-
Humans
-
Male
-
Membrane Proteins / metabolism*
-
Prognosis
-
Prospective Studies
-
Risk Assessment / methods
-
Severity of Illness Index
-
Transcatheter Aortic Valve Replacement / mortality*
Substances
-
CA-125 Antigen
-
MUC16 protein, human
-
Membrane Proteins